{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:04:02Z","timestamp":1792649042151,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ihj.2023.11.267","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:53:35Z","timestamp":1712577215000},"page":"S33-S37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["Role of statins in the management of dyslipidaemia"],"prefix":"10.1016","volume":"76","author":[{"given":"Saumitra","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2023.11.267_bib1","first-page":"1","article-title":"Epidemiological studies related to coronary heart disease: characteristics of men aged 40\u201359 in seven countries","volume":"460","author":"Keys","year":"1966","journal-title":"Acta Med Scand Suppl"},{"key":"10.1016\/j.ihj.2023.11.267_bib2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"B 86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser"},{"key":"10.1016\/j.ihj.2023.11.267_bib3","first-page":"1231","article-title":"Statin: still A superhero or now playing A character role?","volume":"2019","author":"Ray","year":"2019","journal-title":"Medicine Update"},{"key":"10.1016\/j.ihj.2023.11.267_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.ihj.2023.11.267_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ihj.2023.11.267_bib6","first-page":"355","article-title":"Adverse effects of statins: real or myth? Message to statin sceptics","author":"Ray","year":"2019","journal-title":"Cardiol Update"},{"issue":"9","key":"10.1016\/j.ihj.2023.11.267_bib7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11886-022-01729-x","article-title":"SAMSON and the nocebo effect: management of statin intolerance","volume":"24","author":"Krishnamurthy","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.ihj.2023.11.267_bib8","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"International Lipid Expert Panel (ILEP). Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ihj.2023.11.267_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/MOL.0000000000000172","article-title":"Statins and diabetes risk: how real is it and what are the mechanisms?","volume":"26","author":"Robinson","year":"2015","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.ihj.2023.11.267_bib10","first-page":"31","article-title":"Differential effects of different statins on metabolic syndrome","volume":"1","author":"Ray","year":"2020","journal-title":"Int J Atherogenic Diabetic Dyslipidemia"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.267_bib11","first-page":"711","article-title":"Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity","volume":"83","author":"Gillett","year":"2011","journal-title":"Am Fam Physician"},{"issue":"3","key":"10.1016\/j.ihj.2023.11.267_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","article-title":"Statin-induced liver injury patterns: a clinical review","volume":"10","author":"Averbukh","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"9364","key":"10.1016\/j.ihj.2023.11.267_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2023.11.267_bib14","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"9435","key":"10.1016\/j.ihj.2023.11.267_bib15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"8934","key":"10.1016\/j.ihj.2023.11.267_bib16","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ihj.2023.11.267_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"J Vasc Surg"},{"issue":"8","key":"10.1016\/j.ihj.2023.11.267_bib18","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ihj.2023.11.267_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","article-title":"TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?","volume":"93","author":"Waters","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2023.11.267_bib20","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/904742","article-title":"Statins: cardiovascular risk reduction in percutaneous coronary intervention\u2014basic and clinical evidence of hyperacute use of statins","author":"Morales-Villegas","year":"2011","journal-title":"Int J Hypertens"},{"issue":"13","key":"10.1016\/j.ihj.2023.11.267_bib21","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.2018.2444","article-title":"Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial","volume":"319","author":"Berwanger","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.267_bib22","first-page":"279","article-title":"Familial hypercholesterolemia: improving outcomes with newer agents","volume":"8","author":"Ray","year":"2020","journal-title":"Am J Intern Med"},{"issue":"25","key":"10.1016\/j.ihj.2023.11.267_bib23","first-page":"e1082","article-title":"2018AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American heart association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ihj.2023.11.267_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2023.11.267_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ihj.2018.03.011","article-title":"Adaptation of 2016 European Society of Cardiology\/European Atherosclerosis Society guideline for lipid management to Indian patients \u2013 a consensus document","volume":"70","author":"Ray","year":"2018","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2023.11.267_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12944-017-0519-1","article-title":"Lipid management in India: a nationwide, cross-sectional physician survey","volume":"16","author":"Wander","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.ihj.2023.11.267_bib27","first-page":"66330","article-title":"Use of statins in India: a survey to understand the prescribing patterns of physicians in India","volume":"10","author":"Narasinghan","year":"2018","journal-title":"Int J Curr Res"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223004583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223004583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:53:49Z","timestamp":1712577229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483223004583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":27,"alternative-id":["S0019483223004583"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2023.11.267","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of statins in the management of dyslipidaemia","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2023.11.267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}